<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="102648">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02085460</url>
  </required_header>
  <id_info>
    <org_study_id>037-12-001</org_study_id>
    <nct_id>NCT02085460</nct_id>
  </id_info>
  <brief_title>A Phase 2 Trial of Rebamipide Liquid to Determine the Effective Dose for Prevention of Chemoradiotherapy-induced Oral Mucositis in Patients With Head and Neck Cancer</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase 2 Trial of Rebamipide Liquid to Determine the Effective Dose for Prevention of Chemoradiotherapy-induced Oral Mucositis in Patients With Head and Neck Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <authority>Japan: Ministry of Health, Labor and Welfare</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the efficacy and safety of rebamipide liquid for chemoradiotherapy-induced
      oral mucositis in patients with head and neck cancer following administration of rebamipide
      and to determine the optimal dose of rebamipide.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Anticipated">August 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Incidence of oral mucositis graded as severe or worse.</measure>
    <time_frame>77 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Onset time, duration and incidence of oral mucositis.</measure>
    <time_frame>77 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The maximum severity grade for oral mucositis.</measure>
    <time_frame>77 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>77 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>6 times daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2% Rebamipide liquid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 times daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4% Rebamipide liquid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 times daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2% Rebamipide liquid</intervention_name>
    <arm_group_label>2% Rebamipide liquid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>4% Rebamipide liquid</intervention_name>
    <arm_group_label>4% Rebamipide liquid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Head and neck cancer patients scheduled for definitive or postoperative
             chemoradiotherapy.

          -  Patients with a histopathological diagnosis of head and neck cancer and primary tumor
             in one of the following regions.

               1. Definitive therapy: nasopharynx, oropharynx, hypopharynx, or larynx

               2. Postoperative therapy: oral cavity, ropharynx, hypopharynx, or larynx

          -  Patients with no history of chemotherapy, radiotherapy, or chemoradiotherapy for head
             and neck cancer

          -  Patients with an Eastern Cooperative Oncology Group (ECOG) performance status score
             of 0 or 1

          -  Patients who are able to hold fluid in the mouth

          -  Patients who are able to swallow the investigational medicinal product (IMP)

          -  Patients expected to survive for at least 3 months

          -  Patients who have given written informed consent in person

          -  Patients who can stay at or visit the hospital for scheduled examinations and
             observations

          -  Patients who are able to take contraceptive measures to avoid pregnancy of the
             patient or their partner from the time of informed consent until 4 weeks after
             completion of IMP administration

        Exclusion Criteria:

          -  Patients with primary malignant tumors other than head and neck cancer.

          -  Patients with symptomatic viral, bacterial, or fungal infection

          -  Patients with serious renal impairment

          -  Patients with distant metastasis

          -  Patients with severe complications (uncontrolled cardiac disease, diabetes,
             hypertension, etc)

          -  Patients with any of the following laboratory test results:

               1. Neutrophil count: &lt;1500 L

               2. Platelet count: &lt;75000 L

               3. Hemoglobin: &lt;10.0 g/L

               4. Aspartate aminotransferase (AST): &gt;3 times the upper limit of the reference
                  value at the trial site

               5. Alanine aminotransferase (ALT): &gt;3 times the upper limit of the reference value
                  at the trial site

               6. Serum bilirubin: &gt;1.5 times the upper limit of the reference value at the trial
                  site

               7. Serum albumin: &lt;3.0 g/dL

               8. Serum creatinine: &gt;1.5 the upper limit of the reference value at the trial site

               9. Creatinine clearance : &lt;30 mL/min

          -  Patients complicated with autoimmune disease

          -  Patients requiring continuous systemic administration of glucocorticoid

          -  Female patients who are pregnant or lactating, who may possibly be pregnant, or who
             wish to become pregnant

          -  Patients who have participated in any other clinical trial within 4 weeks prior to
             initiation of chemoradiotherapy

          -  Patients who have a history of drug allergy to rebamipide, cisplatin, or other
             platinum compounds

          -  Patients who are otherwise judged by the investigator or sub-investigator to be
             inappropriate for inclusion in the trial
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun-ichi Hashimoto, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Otsuka Pharmaceutical Co., Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Drug Information Center</last_name>
    <phone>+81-3-6361-7314</phone>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Chubu Region</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Chugoku Region</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Kanto Region</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Kinki Region</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Tohoku Region</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 17, 2014</lastchanged_date>
  <firstreceived_date>March 11, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Stomatitis</mesh_term>
    <mesh_term>Mucositis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rebamipide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
